UNIVERSITÀ
DEGLI STUDI
FIRENZE

FLORE

Repository istituzionale dell'Università degli Studi di Firenze

The diagnosis of heart failure in the community. Comparative validation of four sets of criteria in unselected older adults: the

Questa è la Versione finale referata (Post print/Accepted manuscript) della seguente pubblicazione:

Original Citation:

The diagnosis of heart failure in the community. Comparative validation of four sets of criteria in unselected older adults: the ICARe Dicomano Study / M. DI BARI; C. POZZI; M.C. CAVALLINI; F. INNOCENTI; G. BALDERESCHI; W. DE ALFIERI; E. ANTONINI; R. PINI; G. MASOTTI; N. MARCHIONNI. - In: JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. - ISSN 0735-1097. - STAMPA. - 44:(2004), pp. 1601-1608.

Availability:

This version is available at: 2158/312327 since:

Terms of use:

Open Access

La pubblicazione è resa disponibile sotto le norme e i termini della licenza di deposito, secondo quanto stabilito dalla Policy per l'accesso aperto dell'Università degli Studi di Firenze (<https://www.sba.unifi.it/upload/policy-oa-2016-1.pdf>)

Publisher copyright claim:

(Article begins on next page)

The Diagnosis of Heart Failure in the Community

Comparative Validation of Four Sets of Criteria in Unselected Older Adults: The ICARE Dicomano Study

Mauro Di Bari, MD, PhD,*† Claudia Pozzi, MD,* Maria Chiara Cavallini, MD, PhD,*† Francesca Innocenti, MD,*† Giorgio Baldereschi, MD,*† Walter De Alfieri, MD,‡ Enrico Antonini, MS,* Riccardo Pini, MD, FACC,*† Giulio Masotti, MD,*† Niccolò Marchionni, MD*†

Florence and Grosseto, Italy

OBJECTIVES	We sought to compare construct and predictive validity of four sets of heart failure (HF) diagnostic criteria in an epidemiologic setting.
BACKGROUND	The prevalence estimates of HF vary broadly depending on the diagnostic criteria.
METHODS	Data were collected in a survey of community dwellers who were ≥ 65 years of age living in Dicomano, Italy. At baseline, HF was diagnosed with the criteria of the Framingham, Boston, and Gothenburg studies and of the European Society of Cardiology (ESC). Left ventricular mass index and ejection fraction, left atrium systolic dimension, lower extremity mobility disability, summary physical performance score, and 6-min walk test were compared between HF and non-HF participants to test for construct validity of each set of criteria. Predictive validity was evaluated with follow-up assessment of cardiovascular mortality, incident disability, and HF-related hospitalizations. Comparisons were adjusted for demographics, comorbidity, and psychoaffective status.
RESULTS	Of 553 participants, 11.9%, 10.7%, 20.8%, and 9.0% had HF, according to Framingham, Boston, Gothenburg, and ESC criteria, respectively. In terms of construct validity, Framingham and Boston criteria discriminated HF from non-HF participants better than Gothenburg and ESC criteria across the measures of cardiac function and global performance. The Boston criteria showed a superior predictive validity because they indicated a significantly greater adjusted risk of cardiovascular death (hazard ratio 3.9, 95% confidence interval 1.2 to 13.2), incident disability, and hospitalizations in participants with HF.
CONCLUSIONS	The Boston criteria are preferable to Framingham, Gothenburg, and ESC criteria for the diagnosis of HF in older community dwellers because they have good construct validity and more accurately predict cardiovascular death, incident disability, and hospitalizations. (J Am Coll Cardiol 2004;44:1601–8) © 2004 by the American College of Cardiology Foundation

Heart failure (HF) poses a major burden on public health systems of industrialized countries. Its prevalence and incidence sharply increase in older individuals (1,2), in whom this condition is a leading cause of death, morbidity, disability, and hospital admissions (3–5). However, randomized clinical trials of angiotensin-converting enzyme inhibitors (6), angiotensin receptor antagonists (7), beta-blockers (8), and spironolactone (9) have clearly shown that survival and functional outcomes can be effectively improved when HF is recognized in a timely manner.

Unfortunately, the clinical recognition of HF can be difficult, especially at a primary care level. Even experienced physicians frequently disagree on the diagnosis of mildest cases (10), whereas <50% of the diagnoses made by primary care physicians are confirmed after further cardiac assess-

ment (11). Because of comorbidity and atypical clinical manifestations, the diagnosis is particularly challenging in older persons: a recent study reported that primary care physicians often feel uncomfortable in diagnosing HF and in differentiating it from other diseases that are common in late life (12). Thus, the syndrome remains unrecognized and poorly managed in many older patients (12).

Besides clinical practice, difficulties in the diagnosis of HF also impact on its epidemiologic assessment in the population. Prevalence figures reported in the medical literature vary widely (13–17), mainly because different sets of diagnostic criteria have been used. Most of these criteria rarely have been comparatively evaluated and, therefore, it is unknown which set provides the most accurate estimates. The present study was conducted to compare construct and predictive validity of four established sets of criteria for the diagnosis of HF in unselected older community dwellers.

METHODS

In the validation process of a diagnostic instrument, the term *construct validity* indicates the ability of that instrument to represent characteristics (constructs) of the condi-

From the *Department of Critical Care Medicine and Surgery, Unit of Gerontology and Geriatrics, University of Florence, and †Azienda Ospedaliero-Universitaria Careggi, Florence, Italy; and ‡Unit of Geriatrics, Grosseto, Italy. Sponsored in part by the Italian Ministry of Scientific and Technological Research (National Special Project on Heart Failure), by the Regional Government of Tuscany, and by the Azienda Ospedaliera Careggi-Firenze, Italy.

Manuscript received April 16, 2004; revised manuscript received June 24, 2004, accepted July 5, 2004.

Abbreviations and Acronyms

BADL	= basic activities of daily living
ESC	= European Society of Cardiology
GDS	= Geriatric Depression Scale
HF	= heart failure
ICED	= Index of Coexisting Diseases
LASD	= left atrial systolic dimension
LEMD	= lower extremity mobility disability
LV	= left ventricular
LVEF	= left ventricular ejection fraction
LVMI	= left ventricular mass index
MMSE	= Mini Mental State Examination
SPS	= summary performance score
6MWT	= 6-min walk test

tion under examination, whereas *predictive validity* is the ability of the instrument to predict clinically relevant outcomes (18). In this study, HF constructs were considered abnormalities in cardiac structure and function that are typical of the syndrome and limitations in physical performance that are its ultimate consequences. Predictive validity was evaluated by comparing cardiovascular mortality, hospital admissions, and incident disability in subjects with and without the diagnosis of HF.

Study population and protocol. Data were obtained in the “Insufficienza Cardiaca negli Anziani Residenti a Dicomano” (ICARE Dicomano) Study, a longitudinal epidemiologic survey on HF in the elderly that was conducted in Dicomano, a small rural town near Florence, Italy. The methods of the study have been previously detailed (19,20). Briefly, the ICARE Dicomano Study, which is consistent with the principles of the Declaration of Helsinki on clinical research involving human subjects, enrolled in 1995 the entire unselected, community-dwelling elderly (≥ 65 years) population recorded in the City Registry Office. The only exclusion criterion was living in a nursing home.

In a follow-up study, the City Registry Office was consulted to define vital status. Causes of death were ascertained from the International Classification of Diseases-9th edition-coded death certificates and structured questionnaires, which were answered by primary care physicians. Deaths due to International Classification of Diseases codes 410 (myocardial infarction), 430 to 438 (stroke), and 428 (HF) were considered cardiovascular deaths. Clinical data were obtained by interviewing survivors and their primary care physicians.

Data collection. After informed consent, multidimensional, geriatric assessment data, including complete clinical examination, physical performance tests, 12-lead electrocardiogram, and echocardiography, were collected at baseline.

Diagnosis of HF. The diagnosis of HF was based on four previously published instruments: Framingham (16), Boston (21), and Gothenburg criteria (22) and the European Society of Cardiology (ESC) principles (23), as operationalized by Davies et al. (14) and Fischer et al. (24).

Preliminarily, the presence of dyspnea as the main symp-

tom limiting physical activity was investigated using Goldman’s Specific Activity Scale (25), which explores tolerance to exertion in standardized daily activities, grouped into four classes according to the level of energy expenditure in metabolic equivalents (METs), from >7 (class I) to <2 METs or at rest (class IV). The occurrence of orthopnea, paroxysmal nocturnal dyspnea, and pulmonary edema also was recorded.

With the Framingham instrument (16), HF was diagnosed in the presence of two major or one major and two minor criteria, representing signs and symptoms typical of HF. Circulation time ≥ 25 s, reduced vital capacity, and weight loss after diuretics, which were enlisted in the original Framingham diagnostic tool, were not considered in this study.

The Boston instrument (21) explores the presence of symptoms and signs typical of HF in the three categories of history, physical findings, and chest X-ray. A score of 0 to 4 is assigned to each category, providing a summary score from 0 to 12 (Appendix). The original distinction between a definite (score >8) and a probable (score 5 to 7) diagnosis of HF was not maintained in this study, where a score >5 was considered as diagnostic. Chest X-ray was not performed when the sum of scores assigned to history and physical findings was either 0 or >5 because in these two extremes chest X-ray alone would have allowed neither to establish nor to exclude the diagnosis. When indicated, chest X-ray was scored independently by a cardiologist and a pulmonologist; disagreement ($<10\%$ of cases) was resolved by consensus.

Gothenburg criteria (22) take into account history and physical findings to calculate a cardiac score contributing to define, together with specific drug treatment, an HF stage, ranging from 0 (HF absent) to 4 (death due to HF). In this study, a diagnosis of HF based on this instrument was assigned only to participants resulting to have “overt HF” (stages 2 to 3). Stage 4, which can be assigned only in follow-up studies, was not applicable at baseline in the present investigation.

The ESC principles require a combination of symptoms, objective evidence of cardiac dysfunction, and response to treatment in doubtful cases (23). As suggested by the ESC, echocardiography was used to assess the presence of cardiac dysfunction (see the next section). In agreement with Davies et al. (14), reduced left ventricular ejection fraction (LVEF, %), valve dysfunction, and atrial fibrillation were considered cardiac abnormalities supporting the diagnosis. Isolated diastolic abnormality also was taken into account (24) to acknowledge the possible occurrence of HF with preserved systolic function (24,26). Combining Davies’ categories of definite and probable HF (14), the ESC diagnosis was assigned to participants with dyspnea (Specific Activity Scale classification >2) and echocardiographic evidence of cardiac dysfunction.

Echocardiographic examination. Echocardiography was performed with a mechanical sector scanner (Challenger,

3.5 to 2.5 MHz dynamically focused transducer, ESAOTE Biomedica, Genoa, Italy) according to standard methods (27,28). Images were videotaped and stop frames were digitized (TomTec^{P90} System, TomTec Imaging Systems, Munich, Germany) for quantitative analysis by examiners who were blinded to clinical data. At least three measures were averaged in participants in sinus, and five in those in non-sinus rhythm.

Technical acceptability of M-mode images was judged by standardized criteria (29). When M-mode orientation was suboptimal, linear measures were taken from two-dimensional images. Left ventricular (LV) mass was calculated from LV wall thickness and internal dimensions (30) and indexed by body surface area (left ventricular mass index [LVMI], g/m²).

The LV volumes were calculated with the area-length formula, from manually traced endocardial end-diastolic and end-systolic borders from apical four-chamber view images. When this view was unavailable, volumes were calculated with Teichholz's formula from M-mode measures (31). An LVEF <50% was considered as indicative of systolic dysfunction.

Valvular and LV diastolic function was assessed with color, pulsed-wave, and continuous-wave Doppler signals. Aortic stenosis with peak gradient >20 mm Hg, mitral stenosis with area <1.5 cm², or regurgitant lesions >2/4+ were considered significant valve abnormalities. Peak early and late velocities were measured from the pulsed-wave Doppler mitral inflow pattern recorded at the mitral leaflet tips. Isovolumetric relaxation time was measured as the time interval between the end of aortic outflow and the beginning of mitral inflow signal. Isolated diastolic abnormality was suggested in the presence of an LVEF >45% associated with an early/late ratio less than or an isovolumetric relaxation time greater than the age-appropriate limits of 0.50 and 105 ms, respectively (32).

Functional assessment. Because HF impairs blood supply to performing skeletal muscles, functional assessment was considered a relevant component in the evaluation of construct validity of the criteria for the diagnosis of HF.

Baseline functional status was assessed subjectively in terms of self-reported lower extremity mobility disability (LEMD) and objectively by using performance tests. A modified version of the World Health Organization disability questionnaire (33) was used to identify LEMD as difficulty in one or more of six activities involving lower extremity function (transferring in and out of bed, using the toilet, moving in the house, bathing or showering, walking a quarter of mile, climbing stairs) that are pivotal to maintain autonomy in late life (34,35). The number of items in which the participant reported difficulty was taken as a subjective measure of functional limitation.

Objective measures of functional status were the 6-min walk test (6MWT) (36) and a modified version of Guralnik's lower extremity physical performance battery (37). Studies have shown that the distance (m) walked in the

6MWT is a strong prognostic predictor in HF and other clinical conditions (36). The lower extremity physical performance battery is a tool well established in comprehensive geriatric assessment, which includes three tests assessing balance, a walk of short distance, and lower extremity strength (37). Balance is evaluated as the time, up to a maximum of 10 s, the participant is able to maintain standing equilibrium in five tasks of increasing difficulty. Walking ability is assessed as speed in a 4-m path, taking the best result in two trials. Lower extremity strength is indirectly evaluated as time required to stand up five times from a chair. The performance is evaluated by assigning to each test a score from 0 (worst performance) to 4 (best performance) based on the quartile distribution of the test results in a reference older population. A summary performance score (SPS, range 0 to 12) is then calculated as the sum of individual test scores. The SPS predicts important outcomes such as incident physical disability, nursing home admission, and death (37).

In survivors who were not disabled at baseline, incident disability in basic activities of daily living (BADL) was evaluated in the follow-up as onset of need for help in at least one of the following: walking in the house, washing and dressing self, toileting, transferring from bed to chair, and eating (33).

Assessment of comorbidity. The previously described measures of functional status are nonspecific for HF and can be influenced by noncardiac diseases. Thus, they can be used to validate a diagnosis of HF only when other causes of functional limitation are accounted for in multivaried analyses. To this purpose, comorbidities were thoroughly ascertained and quantified.

Diagnostic algorithms, based on questionnaires, physical examination, laboratory tests, and instrumental data (19), were used to identify 14 coexisting diseases. The individual disease severity was weighted using Greenfield's index, which ranges from 0 (disease absent) to 4 (life threatening or uncontrolled disease). The burden of comorbidity was then summarized as Index of Coexisting Diseases (ICED), which is the sum of the individual severity scores (38).

Cognitive impairment and depressive symptoms, which are frequent non-somatic comorbidities of late life not included in the ICED, were evaluated with the Mini Mental State Examination (MMSE) (39) and the Geriatric Depression Scale (GDS) (40).

Analytic procedures. Statistical analysis was performed with SPSS for Windows 10.1 (SPSS Inc., Chicago, Illinois). Continuous variables are reported as mean $\pm$ SEM. Relative frequencies were compared with the chi-squared test. Kappa statistics was used to analyze the agreement between pairs of sets of diagnostic criteria.

To evaluate construct validity, measures of cardiac structure and function (LVMI, LVEF, and left atrial systolic dimension [LASD]) and global functional status (LEMD, 6MWT, and SPS) were compared between HF and non-HF participants in age-adjusted and gender-adjusted

Table 1. Prevalence of Heart Failure According to Different Diagnostic Criteria by Age and by Gender

	Total n (%)	Age (yrs)		Gender	
		65–74 n (%)	75+ n (%)	Men n (%)	Women n (%)
Framingham	66 (11.9)	34 (9.0)	32 (18.4)	31 (13.4)	35 (10.9)
p value		0.002		0.379	
OR (95% CI)		2.3 (1.4–3.8)		0.8 (0.5–1.3)	
Boston	59 (10.7)	32 (8.4)	27 (15.5)	23 (9.9)	36 (11.2)
p value		0.012		0.625	
OR (95% CI)		2.0 (1.2–3.4)		1.1 (0.7–2.0)	
Gothenburg	115 (20.8)	67 (17.7)	48 (27.6)	49 (21.1)	66 (20.6)
p value		0.008		0.873	
OR (95% CI)		1.8 (1.2–2.7)		1.0 (0.6–1.5)	
ESC	50 (9.0)	15 (4.0)	35 (20.1)	19 (8.2)	31 (9.7)
p value		<0.001		0.553	
OR (95% CI)		6.1 (3.2–11.5)		1.2 (0.7–2.2)	

CI = confidence interval; ESC = European Society of Cardiology; OR = odds ratio.

analysis of variance models. The Index of Coexisting Diseases, MMSE, and GDS scores were also entered as covariates in models analyzing differences in functional status.

Predictive validity was evaluated by comparing cardiovascular mortality, incident BADL disability, and HF-related hospitalizations between HF and non-HF participants. Cox's proportional hazards survival model was used to analyze cardiovascular mortality. The proportionality of hazards was assessed with visual inspection of the survival curves. Logistic regression was used to analyze the risk of incident BADL disability and hospital admission. In all analyses, age, gender, and ICED, MMSE, and GDS scores were entered as covariates. A two-tailed p value < 0.05 was considered statistically significant.

RESULTS

Of 864 subjects eligible as of April 25, 1995, 614 underwent cardiologic examination. Reasons for nonparticipation were death or nursing home admission before data collection in 21 cases and refusal in 229. After exclusion of another 61 participants with incomplete data, the final study sample included 553 participants (64.0% of the original cohort), of whom 232 (41.9%) were men. Mean age was 73.0 ± 0.3 years (range, 65 to 94 years). Compared with the 553 participants included, those who were not included were older (76.1 ± 0.4 years; $p < 0.001$) but had a similar proportion of men (45%; $p = 0.383$). In most eligible nonparticipating (286 of 311) and participating subjects (538 of 553), clinical data could be obtained from primary care physicians, who reported a diagnosis of HF less frequently in those who did participate (56 of 538; 10.4%), as compared with those who did not (59 of 286; 20.6%; $p < 0.001$).

Prevalence of HF and diagnostic concordance. HF was diagnosed in 11.9%, 10.7%, 20.8%, and 9.0% of participants using Framingham, Boston, Gothenburg, and ESC criteria, respectively. Prevalence figures increased with age but were similar in men and women (Table 1). As shown by kappa

values between 0.05 and 0.59, the agreement between diagnostic criteria ranged from poor to only moderate even when comparing criteria that yielded similar prevalence (Framingham, Boston, and ESC criteria) (Fig. 1).

Construct validity. Participants diagnosed with Framingham, Boston, and Gothenburg criteria but not with ESC criteria had an LVMI greater than those without HF; Framingham criteria maximized the difference in LVMI between HF and non-HF participants (Fig. 2A). With all criteria, HF participants had significantly lower LVEF than non-HF participants; the difference was greater when the diagnosis was made following ESC criteria (Fig. 2B). When LASD was considered, only Framingham, Boston, and Gothenburg criteria showed significant differences between HF and non-HF participants, slightly greater with Boston criteria (Fig. 2C).

Gothenburg and ESC criteria failed to show any significant difference in physical functioning measures between HF and non-HF participants. Conversely, when the diagnosis was based on Framingham or Boston criteria, HF participants reported more difficulties in mobility tasks, had a lower SPS, and walked less at the 6MWT, even after adjusting for covariates (Fig. 3). The difference between HF and non-HF participants was maximized using Framingham criteria for LEMD (Fig. 3A) and SPS (Fig. 3B) and Boston criteria for the 6MWT (Fig. 3C).

Predictive validity. In a three-year follow-up, 18 cardiac and 29 noncardiac deaths were recorded (cumulative mor-

Figure 1. Agreement between pairs of diagnostic criteria for heart failure (HF). ESC = European Society of Cardiology.

Figure 2. Left ventricular mass index (LVMI) (A), ejection fraction (LVEF) (B), and left atrium systolic dimension (LASD) (C) were compared between participants with and without heart failure (HF) according to different criteria. Data are least square means, adjusted for age and gender. Δ is the difference between non-HF and HF participants. **Open bars** = non-HF; **closed bars** = HF. ESC = European Society of Cardiology; SEM = standard error of the mean.

tality 8.5%). Cardiovascular mortality was 7.6%, 10.2%, 3.5%, and 6.0% in participants labeled as HF using Framingham, Boston, Gothenburg, and ESC criteria, respectively. In Cox's regression models adjusted for age, gender, MMSE, GDS, and ICED, only Boston criteria predicted cardiovascular death (Fig. 4).

Of the survivors, 446 who were not disabled at baseline were interviewed in the follow-up to detect changes in their functional status. New BADL disability was identified in 35 cases (7.8%). Cumulative incidence of BADL disability was 21.3%, 26.2%, 10.1%, and 26.5% in participants diagnosed with HF using Framingham, Boston, Gothenburg, and ESC criteria, respectively; the corresponding figures for non-HF participants were 6.3%, 5.9%, 7.3%, and 6.3%. In logistic regression models, adjusted for age, gender, MMSE, GDS, and ICED, only Boston criteria predicted incident BADL disability (Table 2).

The absolute risk of HF-related hospital admission in the follow-up was 6.1%, 6.8%, 3.5%, and 0% in participants with and 0.6%, 0.6%, 0.7%, and 1.4% in those without the diagnosis based on Framingham, Boston, Gothenburg, and ESC criteria, respectively. In adjusted logistic regression models, only Framingham and Boston criteria predicted a significantly higher risk of HF-related hospital admissions; the odds ratio was slightly higher for Boston than for Framingham criteria (Table 3).

Figure 3. Number of items with self-reported lower extremity mobility difficulty (LEMD) (A), lower extremity function summary performance score (SPS) (B), and distance walked in 6 min (6MWT) (C) compared between participants with and without heart failure (HF) according to different criteria. Data are least square means, adjusted for age, gender, Mini Mental State Examination, Geriatric Depression Scale, and Index of Coexisting Diseases. **Open bars** = non-HF; **closed bars** = HF. ESC = European Society of Cardiology; SEM = standard error of the mean.

DISCUSSION

In this community-based sample of older persons, the prevalence of HF obtained with four sets of established diagnostic criteria varied between 9.0% and 20.8%. Even when instruments that yielded similar prevalence were compared, the diagnostic agreement was only poor to

Figure 4. Cardiovascular mortality compared between participants with and without heart failure (HF) according to different criteria. Cox's proportional hazard survival models, adjusted for age, gender, Mini Mental State Examination, Geriatric Depression Scale, and Index of Coexisting Diseases. CI = confidence interval; CV = cardiovascular; ESC = European Society of Cardiology; HR = hazard ratio.

Table 2. Multivariate Prediction of Incident Disability in Basic Activities of Daily Living in Participants With a Baseline Diagnosis of Heart Failure According to Different Criteria

	OR*	95% CI*	p Value*
Framingham	2.4	0.8–6.8	0.102
Boston	4.2	1.4–12.6	0.011
Gothenburg	1.1	0.4–3.2	0.826
ESC	2.6	0.9–7.5	0.077

*From separate logistic regression models, each adjusted for age, gender, Mini Mental State Examination, Geriatric Depression Scale, and Index of Coexisting Diseases. Abbreviations as in Table 1.

moderate. Because such a misclassification could have important consequences in clinical practice and in epidemiologic research, we deemed as necessary a comparative validation of these diagnostic tools. Framingham and Boston criteria had better construct validity than Gothenburg and ESC criteria and also exhibited the closest diagnostic concordance. When predictive validity was eventually taken into account, the Boston instrument was consistently associated with a greater risk of cardiovascular death, incident BADL disability, and HF-related hospital admissions. Thus, our results indicate that Boston criteria are superior for the diagnosis of HF in unselected older persons living in the community.

Three of four criteria considered in this study had been previously validated, mostly in terms of concurrent criterion validity. Boston criteria were originally validated against a capillary wedge pressure >12 mm Hg (21) and, subsequently, together with Framingham criteria, in a comparative study against an LVEF $\leq 40\%$ (41). Gothenburg criteria were developed and validated in older men by comparison with echocardiographic measures of LV function (22). Furthermore, the performance of these three criteria was evaluated using the diagnosis of a cardiologist as a gold standard (42). Criteria from the ESC were derived from consensus and have not been previously validated.

The validation procedures followed in previous investigations can be criticized. Heart failure is a clinical syndrome with multiple etiologies, diverse pathophysiology, and a frequently atypical presentation at older ages. Because of these characteristics, no single measure and, in particular, no single hemodynamic abnormality can be taken as the reference standard to validate the diagnosis. Capillary wedge

Table 3. Multivariate Prediction of Hospital Admissions for Heart Failure in Participants With a Baseline Diagnosis of Heart Failure According to Different Criteria

	OR*	95% CI*	p Value*
Framingham	6.9	1.3–36.1	0.022
Boston	8.7	1.5–51.5	0.017
Gothenburg	5.1	0.9–27.7	0.058
ESC	NA	NA	NA

*From separate logistic regression models, each adjusted for age, gender, Mini Mental State Examination, Geriatric Depression Scale, and Index of Coexisting Diseases. OR could not be calculated for ESC criteria because no participant with an ESC-based diagnosis had hospital admissions due to heart failure in the follow-up.

NA = not applicable; other abbreviations as in Table 1.

pressure commonly is increased in patients with HF, yet after diuretic or vasodilator treatment, it can be normal at rest and increase only on exertion. Left ventricular ejection fraction is low when HF is due to systolic dysfunction, but by definition it is normal in the presence of diastolic dysfunction. Finally, even cardiologists may disagree on the presence of HF, at least in mildest cases and, therefore, the judgment of a single clinician can be hardly assumed as a gold standard.

Following a different approach, we aimed at identifying the instrument that would provide the best discrimination between participants labeled as HF versus non-HF across a spectrum of measures pertinent to the two domains of construct and predictive validity. In the domain of construct validity, LVEF, LVMI, and LASD were selected as indicators of the underlying structural and functional abnormalities of the heart. On average, LVEF is indeed expected to be lower, and LVMI and LASD greater, in subjects with HF than in those without HF. Measures of physical functioning also were considered because the ultimate effect of HF is to reduce blood supply to metabolically active tissues, such as skeletal muscles, therefore limiting physical performance. The three measures considered in the domain of predictive validity represent expected consequences of HF, which reduces life expectancy, compromises functional independence, and causes frequent hospitalizations. Because these outcomes are not exclusive of HF and can be due to a variety of conditions, the comparisons between HF and non-HF participants were adjusted for demographics, comorbidity, and cognitive and affective status. Thus, our validation procedure encompassed thoroughly the clinical complexity of HF while controlling for a variety of possible confounders. We believe that this analytic approach and the population-based nature of our sample represent major strengths of this study. It should be further emphasized that, to our knowledge, no previous study examined predictive validity of diagnostic criteria for HF.

The superiority of Boston criteria likely depends on their well-balanced scoring of history, physical findings, and chest X-ray. However, it also should be pointed out that this instrument, although valid and preferable over the others tested in this study, relies heavily on the presence of dyspnea as the leading complaint. This symptom is neither specific nor sensitive for HF in older patients (43). On one hand, shortness of breath is reported in the presence of many noncardiac diseases (44), including a condition common but usually overlooked in the elderly, such as thoracic kyphosis (45). On the other hand, in late life HF may present atypically, with a sudden decline of cognitive or physical functioning and negligible respiratory symptoms (46). We would argue that diagnostic criteria for HF, specifically targeting older persons, should rely less on dyspnea and rather include items on atypical presentations. Therefore, the Boston criteria might be refined along this line, to further improve their diagnostic accuracy.

Study limitations. Some study limitations must be acknowledged. The study sample was relatively small, which might have limited the assessment of the validity for some of the analyzed diagnostic criteria. On the other hand, it is likely that a larger sample size would have increased the differences in performance of the diagnostic instruments, therefore leaving the overall results of the study substantially unchanged. Eligible residents in Dicomano who did not participate may pose a selection bias to data interpretation because they were older than those who participated and more often were reported by their physicians as having HF. However, the accuracy of the diagnosis reported by primary care physicians should be questioned because it did not rely on uniform assessments and criteria. The mortality of participants labeled as HF was lower than expected in such an old population, suggesting that milder forms of HF prevailed in participants who were assessed. Yet, this possibly reinforces the validity of our findings because mildest cases are more difficult to recognize.

Even with these limitations, we believe that our findings have remarkable implications in the clinical and public health fields. The demonstration that Boston criteria are more accurate than others may provide clinicians with an instrument of proven validity, therefore possibly overcoming the difficulties they admittedly encounter in the diagnosis of HF in older persons. In the public health arena, these results suggest that the Boston criteria should be preferred in future epidemiologic surveys of HF. To some extent, they might also challenge the available information on HF epidemiology obtained with less accurate instruments.

Reprint requests and correspondence: Dr. Mauro Di Bari, Department of Critical Care Medicine and Surgery, Unit of Gerontology and Geriatrics, University of Florence, via delle Oblate, 4, 50141 Florence, Italy. E-mail: dibari@unifi.it.

REFERENCES

1. Ho KKL, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham study. *J Am Coll Cardiol* 1993;22 Suppl A:6A-13A.
2. Kannel WB, Belanger AJ. Epidemiology of heart failure. *Am Heart J* 1991;121:951-7.
3. Ho KK, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. *Circulation* 1993;88:107-15.
4. McMurray JJ, Petrie MC, Murdoch DR, Davie AP. Clinical epidemiology of heart failure: public and private health burden. *Eur Heart J* 1998;19 Suppl P:P9-16.
5. Stewart S, Jenkins A, Buchan S, McGuire A, Capewell S, McMurray JJ. The current cost of heart failure to the National Health Service in the UK. *Eur J Heart Fail* 2002;4:361-71.
6. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). *N Engl J Med* 1987;316:1429-35.
7. Sharma D, Buyse M, Pitt B, Rucinska EJ. Meta-analysis of observed mortality data from all-controlled, double-blind, multiple-dose studies of losartan in heart failure. Losartan Heart Failure Mortality Meta-analysis Study Group. *Am J Cardiol* 2000;85:187-92.
8. Packer M, Fowler MB, Roecker EB, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. *Circulation* 2002;106:2194-9.
9. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. *N Engl J Med* 1999;341:709-17.
10. Hlatky MA, Haney T, Barefoot JC, et al. Medical, psychological and social correlates of work disability among men with coronary artery disease. *Am J Cardiol* 1986;58:911-5.
11. Remes J, Miettinen H, Reunanen A, Pyorala K. Validity of clinical diagnosis of heart failure in primary health care. *Eur Heart J* 1991;12:315-21.
12. Fuat A, Hungin AP, Murphy JJ. Barriers to accurate diagnosis and effective management of heart failure in primary care: qualitative study. *BMJ* 2003;326:196.
13. Ceia F, Fonseca C, Mota T, et al. Prevalence of chronic heart failure in Southwestern Europe: the EPICA study. *Eur J Heart Fail* 2002;4:531.
14. Davies M, Hobbs F, Davis R, et al. Prevalence of left-ventricular systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening study: a population based study. *Lancet* 2001;358:439-44.
15. Eriksson H, Svärdsudd K, Larsson B, et al. Risk factors for heart failure in the general population: the study of men born in 1913. *Eur Heart J* 1989;10:647-56.
16. McKee PA, Castelli WP, McNamara P, Kannel WB. The natural history of congestive heart failure: the Framingham study. *N Engl J Med* 1971;285:1441-6.
17. Shoenen DD, Arretia M, Leaverton PE, Ross EA. Prevalence and mortality rate of congestive heart failure in the United States. *J Am Coll Cardiol* 1992;20:301-6.
18. Streiner D, Norman G. Validity. In: Streiner D, Norman G, editors. *Health Measurement Scales. A Practical Guide to Their Development and Use*. 3rd edition. Oxford: Oxford University Press, 2003.
19. Di Bari M, Marchionni N, Ferrucci L, et al. Heart failure in community-dwelling older persons: aims, design and adherence rate of the ICARE Dicomano project: an epidemiologic study. *Insufficienza Cardiaca negli Anziani Residenti a Dicomano*. *J Am Geriatr Soc* 1999;47:664-71.
20. Pini R, Cavallini M, Bencini F, et al. Cardiovascular remodeling is greater in isolated systolic hypertension than in diastolic hypertension in older adults: the Insufficienza Cardiaca negli Anziani Residenti (ICARE) a Dicomano Study. *J Am Coll Cardiol* 2002;40:1283-9.
21. Carlson KJ, Lee DCS, Goroll AH, Leahy M, Johnson RA. An analysis of physicians' reasons for prescribing long-term digitalis therapy in outpatients. *J Chron Dis* 1985;38:733-9.
22. Eriksson H, Caidhal K, Larsson B, et al. Cardiac and pulmonary causes of dyspnea—validation of a scoring test for clinical-epidemiological use: the study of men born in 1913. *Eur Heart J* 1987;8:1007-14.
23. Guidelines for the diagnosis of heart failure. The Task Force on Heart Failure of the European Society of Cardiology. *Eur Heart J* 1995;16:741-51.
24. Fischer M, Baessler A, Hense HW, et al. Prevalence of left ventricular diastolic dysfunction in the community. Results from a Doppler echocardiographic-based survey of a population sample. *Eur Heart J* 2003;24:320-8.
25. Goldman L, Hashimoto B, Cook F, Loscalzo A. Comparative reproducibility and validity of systems for assessing cardiovascular functional class: advantages of a new specific activity scale. *Circulation* 1981;64:1227-34.
26. Kitzman DW. Diastolic heart failure in the elderly. *Heart Fail Rev* 2002;7:17-27.
27. Sahn DJ, De Maria AN, Kisslo J, Weiman A. The Committee on M-mode Standardization of the American Society of Echocardiography. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. *Circulation* 1978;58:1072-83.
28. Di Bari M, Cavallini M, Kitzman D, et al. Limited utility of the subcostal view for the echocardiographic evaluation of left ventricular mass in unselected older persons with missing parasternal view. *Int J Cardiol* 2004. In Press.

29. Schieken RM, Clarke WR, Mahoney LT, Lauer RM. Measurement criteria for group echocardiographic studies. *Am J Epidemiol* 1979; 110:504–14.
30. Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. *Am J Cardiol* 1986;57:450–8.
31. Teichholz LE, Kreulen T, Herman MV, Gorlin R. Problems in echocardiographic volume determinations: echocardiographic-angiographic correlations in the presence or absence of asynergy. *Am J Cardiol* 1976;37:7–11.
32. How to diagnose diastolic heart failure. European Study Group on Diastolic Heart Failure (review). *Eur Heart J* 1998;19:990–1003.
33. Heikkinen E, Waters WE, Brzezinski ZJ. The elderly in eleven countries. A socio-medical survey. Copenhagen: WHO Regional Office for Europe Edt. WHO, Public Health in Europe 21, 1983.
34. Ferrucci L, Guralnik JM, Bandinelli S, et al. The development of disability in older persons: relationship with mortality and quality of life. In: Ferrucci L, Heikkinen E, Waters WE, Baroni A, editors. *Health and Quality of Life in Older Europeans*. Florence: INRCA-WHO, 1995:31–66.
35. Fried LP, Guralnik JM. Disability in older adults: evidence regarding significance, etiology, and risk. *J Am Geriatr Soc* 1997;45:92–100.
36. Bittner V, Weiner DH, Yusuf S, et al. Prediction of mortality and morbidity with a 6-minute walk test in patients with left ventricular dysfunction. *JAMA* 1993;270:1702–7.
37. Guralnik JM, Ferrucci L, Simonsick E, Salive ME, Wallace RB. Lower-extremity function in persons over the age of 70 years as predictor of subsequent disability. *N Engl J Med* 1995;332:556–61.
38. Greenfield S, Apolone G, McNeil BJ, Cleary PD. The importance of co-existent disease in the occurrence of postoperative complications and one-year recovery in patients undergoing total hip replacement. Comorbidity and outcomes after hip replacement. *Med Care* 1993;31:141–54.
39. Folstein MF, Folstein SE, McHugh PR. “Mini-Mental State”: a practical method for grading the cognitive state of patients for the clinician. *J Psychiatr Res* 1975;12:189–98.
40. Brink TL, Yesavage JA, Lum O, Heersema PH, Adey M, Rose TL. Screening test for geriatric depression. *Clin Gerontol* 1982;1:37–44.
41. Marantz PR, Tobin JN, Wassertheil-Smoller S, et al. The relationship between left ventricular systolic function and congestive heart failure diagnosed by clinical criteria. *Circulation* 1988;77:607–12.
42. Mosterd A, Hoes AW, de Bruyne MC, et al. Prevalence of heart failure and left ventricular dysfunction in the general population: the Rotterdam Study. *Eur Heart J* 1999;20:447–55.
43. Lien CT, Gillespie ND, Struthers AD, McMurdo ME. Heart failure in frail elderly patients: diagnostic difficulties, co-morbidities, poly-pharmacy and treatment dilemmas. *Eur J Heart Fail* 2002;4:91–8.
44. Mahler DA, Fierro-Carrion G, Baird JC. Evaluation of dyspnea in the elderly. *Clin Geriatr Med* 2003;19:19–33.
45. Di Bari M, Chiarlone M, Matteuzzi D, et al. Thoracic kyphosis and ventilatory dysfunction in unselected older persons: an epidemiological study in Dicomano, Italy. *J Am Geriatr Soc* 2004;52:909–15.
46. Tresch DD. The clinical diagnosis of heart failure in older patients. *J Am Geriatr Soc* 1997;45:1128–33.

APPENDIX

For the Boston criteria for the diagnosis of heart failure, please see the October 20, 2004, issue of *JACC* at www.onlinejacc.org.